Therapy of established experimental Pseudomonas aeruginosa infections with oral ciprofloxacin and five human monoclonal antibodies against lipopolysaccharide antigens.
Collins
M S
MS
Preclinical Microbiology and Immunology, Cutter Biological, Division of Miles Inc., Berkeley, Calif.
Ladehoff
D
D
Mehton
N S
NS
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000942:Antigens, Bacterial / Q000276:immunology*; D002056:Burns / Q000150:complications; D002481:Cellulitis / Q000188:drug therapy / Q000209:etiology / Q000628:therapy; D002939:Ciprofloxacin / Q000627:therapeutic use*; D007167:Immunotherapy; D008070:Lipopolysaccharides / Q000276:immunology*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009503:Neutropenia / Q000150:complications; D011015:Pneumonia, Aspiration / Q000150:complications; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000382:microbiology / Q000628:therapy*; D011550:Pseudomonas aeruginosa / Q000276:immunology*; D014946:Wound Infection / Q000188:drug therapy / Q000209:etiology / Q000628:therapy
D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D008070:Lipopolysaccharides; D002939:Ciprofloxacin